Dogwood Therapeutics, Inc.
DWTX
$5.37
$1.1025.76%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.70M | 4.31M | 3.44M | 3.63M | 3.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.23M | 5.82M | 4.80M | 5.20M | 5.45M |
| Operating Income | -12.23M | -5.82M | -4.80M | -5.20M | -5.45M |
| Income Before Tax | -12.35M | -5.73M | -4.68M | -5.07M | -5.30M |
| Income Tax Expenses | -500.00 | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.35 | -5.73 | -4.68 | -5.07 | -5.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.35M | -5.73M | -4.68M | -5.07M | -5.30M |
| EBIT | -12.23M | -5.82M | -4.80M | -5.20M | -5.45M |
| EBITDA | -7.54M | -- | -- | -- | -- |
| EPS Basic | -11.17 | -6.31 | -5.87 | -6.68 | -7.07 |
| Normalized Basic EPS | -6.73 | -3.94 | -3.67 | -4.18 | -4.42 |
| EPS Diluted | -11.17 | -6.31 | -5.87 | -6.68 | -7.07 |
| Normalized Diluted EPS | -6.73 | -3.94 | -3.67 | -4.18 | -4.42 |
| Average Basic Shares Outstanding | 4.11M | 3.57M | 3.22M | 3.04M | 3.00M |
| Average Diluted Shares Outstanding | 4.11M | 3.57M | 3.22M | 3.04M | 3.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |